Commercialisation of Remplir™ into US Market Continues to Build Momentum

Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir™ in the US. Key achievements include:

• Ten surgeries have now taken place in the US. Experience in existing markets has demonstrated the importance of these early surgeries in the path towards more widespread adoption.
• 36 applications have been lodged to hospital Value Assessment Committees (VACs) with 3 approvals already received. VAC approval is an important and necessary step in achieving widespread surgical adoption in the US hospital system.
• 4,000 Remplir units have been shipped to Orthocell’s US logistics provider, Uniphar, for use in US surgical procedures. All units have been manufactured at the Company’s manufacturing facility in Western Australia.
• Two new employees have been hired in the US, including a regional sales director with direct experience in the nerve repair product market.

Orthocell CEO, Paul Anderson, said: “We continue to make excellent progress in the US with surgeons building familiarity through early surgical procedures. We’ve seen the strategic importance of these early procedures in our successful market launches of Remplir in Australia and Singapore. Our network of distributors remains an important avenue to market and they have been instrumental in identifying key hospitals for us to target VAC approvals. This is the next important step for us in order to achieve more widespread adoption of Remplir, which in turn will drive revenue generation for Orthocell.” Click to read the ASX release.